Holen Sie sich die Stockscreener-App
3.32
3.77%
-0.13
Handel nachbörslich:
3.36
0.04
+1.20%
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Agenus, Inc. to Host Earnings Call - ACCESS Newswire
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Business Wire
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Agenus reports promising sarcoma study results - MSN
Incyte Backs Out of Immuno-Oncology Pact With Agenus - BioSpace
Incyte exits immuno-oncology pact, leaving Agenus weighing options for assets - Fierce Biotech
Agenus IncIncyte To Terminate Agreement With Agenus Effective February 2026 - Marketscreener.com
Agenus Regains Rights to LAG-3 and TIM-3 Programs - TipRanks
Agenus Inc. and Incyte Corporation Provides Update on License, Development, and Commercialization Agreement - Marketscreener.com
Vaccine Adjuvants Market Next Big Thing | Major Giants- GlaxoSmithKline, Novavax, Agenus - openPR
AGEN Shareholders Have Opportunity to Lead Agenus Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts - Defense World
What is William Blair's Forecast for Agenus FY2024 Earnings? - MarketBeat
Reviewing Innate Pharma (NASDAQ:IPHA) and Agenus (NASDAQ:AGEN) - Defense World
FY2024 Earnings Forecast for Agenus Issued By William Blair - Defense World
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development - NewsBreak
Agenus reports publication of data from bot/bal combination in JOCO - TipRanks
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas | Business Wire - businesswire.fr
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data - Endpoints News
Shareholders that Lost Money on Agenus Inc. (AGEN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright - Defense World
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewswire Inc.
Agenus reports promising colorectal cancer treatment data - MSN
Barclays PLC Buys 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease - BioSpace
Agenus reports promising colorectal cancer treatment data By Investing.com - Investing.com UK
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - Morningstar
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Cervical Cancer Market Expected to Experience Major Growth - openPR
What Makes Agenus (AGEN) a New Buy Stock - Yahoo Finance
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Stock Holdings Lessened by Jane Street Group LLC - Defense World
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Analysts - MarketBeat
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease - GlobeNewswire
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease Type, VaccineGlobal Forecast to 2029 with GSK, Seppic, Croda, SPI Pharma, Phibro Animal Health, Agenus, Dynavax Technologies Dominating - Yahoo Finance UK
Barclays PLC Purchases 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
State Street Corp Boosts Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus Inc. (NASDAQ:AGEN) Short Interest Up 6.5% in December - Defense World
HighTower Advisors LLC Boosts Holdings in Agenus Inc. (NASDAQ:AGEN) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - The Eastern Progress Online
AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Invest - GuruFocus.com
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Inve - GuruFocus.com
Agenus (AGEN) Stock Surges Amid Positive Market Movement - GuruFocus.com
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers - Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
BNP Paribas Financial Markets Acquires 37,866 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus (AGEN) Stock Plummets 5.08% Amidst Mixed Ratings - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):